

Weekly COVID-19 Breakthrough Infections Report

Clark County, Nevada

Date: December 6, 2022

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations








Table 1: Population Characteristics of COVID-19 Breakthrough Cases

	Overal	
All	<i>N</i> 124763 1	% ^^
Age (in years)	124703 1	
0-4	3	0
5-11	1510	1
12-17	5837	5
18-24	10778	9
25-49	55052	
50-64		24
65+	21978	
Gender	21970	10
Male	54384	44
Female	69429	56
Unknown	950	1
Race/Ethnicity	930	'
Hispanic	25615	21
White	39325	32
Black	9663	8
API	15823	13
AEA	432	0
Other	9047	7
Unknown	24858	20
Travel History	24030	20
Yes	5259	4
No	32436	26
NO Unknown	32430 87068	70
Hospitalization	87000	70
-	2020	2
Yes No	3038 36691	29
Unknown	85034	68
Death	65034	00
	1104	1
Yes No	1104 9071	1 7
	114588	
Unknown	114566	92
Vaccine Type	02200	67
Pfizer	83299	67
Novavax	5 1056	0
Unknown Moderna	1056 33508	27
	6894	6
Janssen		
Emergen Underlying Conditions	1	0
	17000	11
Yes	17898	14
No	106865	86

Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
852037	124763	1466137	463741	14643	31630



Table 3:Population Characteristics of COVID-19 Breakthrough Hospitalizations

	Over	Overall	
	Ν	%	
All	3038	100	
Age (in years)			
5-11	5	0	
12-17	18	1	
18-24	31	1	
25-49	318	10	
50-64	529	17	
65+	2137	70	
Gender			
Male	1636	54	
Female	1398	46	
Unknown	4	0	
Race/Ethnicity			
Hispanic	372		
White	1767		
Black	346	11	
API	298		
AEA	14	_	
Other	93	_	
Unknown	148	5	
Travel History			
Yes	132	4	
No	1559		
Unknown	1347	44	
Death			
Yes	783		
No	532		
Unknown	1723	57	
Vaccine Type			
Pfizer	1772		
Unknown	72	2	
Moderna	960		
Janssen	234	8	
Underlying Conditions			
Yes	2190	72	
No	848	28	



Table 4:Population Characteristics of COVID-19 Breakthrough Deaths

	Over	all
	Ν	%
All	1104	100
Age (in years)	•	
25-49	33	3
50-64	134	12
65+	937	85
Gender		
Male	659	60
Female	445	40
Race/Ethnicity		
Hispanic	122	11
White	735	67
Black	118	11
API	111	10
AEA	6	1
Other	9	1
Unknown	3	0
Hospitalization		
Yes	783	71
No	73	7
Unknown	248	22
Vaccine Type		
Pfizer	604	55
Unknown	25	2
Moderna	360	33
Janssen	115	10
Underlying Conditions		
Yes	639	58
No	465	42

Table 5: Breakthrough Death Rates

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
852037	1104	1466137	8004	130	546

^{*} Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson S Janssen vaccine.



Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Outcome	N	%
Yes	2190	72
No	848	28
Yes	1396	N/A
Yes	123	N/A
Yes	658	N/A
Yes	55	N/A
Yes	430	N/A
Yes	812	N/A
Yes	189	N/A
Yes	583	N/A
Yes	266	N/A
	Yes No Yes	Yes 2190 No 848 Yes 1396 Yes 123 Yes 658 Yes 55 Yes 430 Yes 812 Yes 189 Yes 583

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	639	58
	No	465	42
Hypertension	Yes	409	N/A
Immunocompromised	Yes	47	N/A
Chronic Heart Disease	Yes	232	N/A
Chronic Liver Disease	Yes	20	N/A
Chronic Kidney Disease	Yes	175	N/A
Diabetes	Yes	247	N/A
Neurologic/Neurodevelopmental	Yes	58	N/A
Chronic Lung Disease	Yes	185	N/A
Historically Healthy	Yes	24	N/A

Notes:

^{*} White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

^{*} The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

^{*} The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).